Larotrectinib Has Antitumor Activity in TRK+ Pediatric Solid Tumors [Research Watch]

Larotrectinib achieved a 93% response rate in pediatric patients with TRK fusion–positive tumors.

from Cancer via ola Kala on Inoreader https://ift.tt/2v8Exxy
via IFTTT